Phio Pharmaceuticals Corp. (PHIO) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+291.8%

$3.45

vs $0.88 price

Levered DCF

$3.51

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

-14.25

Distress zone

Rating

C+

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-0.72×	-1.98×	-0.15×	-0.45×	-0.97×	-1.4×	-0.49×	-0.32×
P/B	0.31×	0.3×	0.2×	0.47×	0.58×	0.95×	0.75×	0.17×
P/S	0×	0×	0×	0×	0×	0×	206.15×	16.81×
EV / EBITDA	1.7×	0.56×	0.65×	0.58×	0.83×	0.15×	0.23×	1.72×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	100.0%	-3034.8%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	-42795.2%	-5336.2%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	-42419.0%	-5333.3%
Current ratio	49.37×	5.65×	5.71×	6.42×	8.06×	6.91×	3.88×	8.69×
Debt / equity	0×	0×	0×	0.02×	0.01×	0.05×	0.09×	0×
Interest coverage	0×	0×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-43.2%	-151.4%	-140.1%	-105.9%	-60.6%	-67.6%	-155.0%	-54.2%
Return on invested capital	-43.8%	-156.4%	-139.4%	-104.1%	-60.8%	-64.4%	-143.4%	-54.2%
Return on assets	-40.5%	-124.6%	-115.6%	-89.6%	-52.8%	-55.9%	-110.8%	-48.0%
Free cash flow yield	-127.2%	-501.8%	-680.6%	-241.7%	-92.9%	-71.6%	-201.4%	-324.3%
Earnings yield	-138.4%	-504.4%	-685.2%	-226.5%	-103.7%	-71.3%	-205.8%	-317.2%
Enterprise value	-$14.7M	-$4M	-$6.9M	-$6.5M	-$10.9M	-$1.3M	-$2.1M	-$12.6M
Net debt / EBITDA	2.42×	0.76×	0.79×	1.03×	1.8×	1.56×	0.72×	2.04×
Cash conversion cycle (days)	-34	-25	-38	-41	-12	-72	0	-46